THYMOSIN BETA-4 FRAGMENT / TISSUE-REPAIR RESEARCH
TB-500 is an acetylated seven-amino-acid fragment corresponding to residues 17–23 of thymosin beta-4. Direct evidence specific to TB-500 is limited, and findings from full-length thymosin beta-4 should not be treated as interchangeable evidence.
PRIMARY RESEARCH AREAS
Actin-binding biology; endothelial-cell migration; angiogenesis-related signaling; tissue-repair models; wound-healing research
EVIDENCE LEVEL
Direct evidence specific to TB-500 is limited; much of the broader literature concerns full-length thymosin beta-4 or the LKKTETQ actin-binding region in experimental systems.
TB-500 has been analytically identified as the N-terminally acetylated 17–23 fragment of human thymosin beta-4, with the sequence Ac-LKKTETQ.
This fragment contains the central actin-binding region of thymosin beta-4 and has shown biological activity in experimental systems related to endothelial-cell migration, angiogenesis, and wound-repair biology.
However, TB-500 should not be treated as interchangeable with the full-length 43-amino-acid thymosin beta-4 peptide. Human clinical research cited for thymosin beta-4 does not automatically establish clinical effects for TB-500.
TB-500 is commonly discussed alongside thymosin beta-4, but the two are not the same molecular entity.
A 2012 analytical study identified TB-500 as the N-terminally acetylated 17–23 fragment of human thymosin beta-4, Ac-LKKTETQ. Full-length thymosin beta-4 is a 43-amino-acid peptide, whereas TB-500 represents only a short central fragment.
That distinction matters because much of the published wound-healing, inflammatory, and human clinical literature concerns full-length thymosin beta-4 rather than TB-500 itself.
The sequence LKKTETQ corresponds to the central actin-binding region of thymosin beta-4.
Experimental work has shown that this short region contributes to endothelial-cell migration, angiogenesis-related activity, and wound-repair biology. Studies using fragments and synthetic peptides suggest that the actin-binding motif contains biologically active information from the larger parent peptide.
However, the biological activity of a peptide fragment does not mean that it reproduces the full pharmacology, tissue distribution, stability, or clinical effects of full-length thymosin beta-4.
Full-length thymosin beta-4 is a major intracellular G-actin-sequestering peptide. Its central LKKTETQ-containing region is involved in actin binding and has been implicated experimentally in cell migration and angiogenesis.
Research using the short actin-binding sequence has reported effects on endothelial-cell migration and vascular sprouting in experimental systems.
These findings provide mechanistic context for TB-500 research, but mechanistic activity should not be interpreted as established therapeutic efficacy.
Direct TB-500 evidence: Analytical research has identified TB-500 as Ac-LKKTETQ, the acetylated 17–23 fragment of thymosin beta-4. Much of the published TB-500 literature has focused on analytical detection and anti-doping applications rather than controlled therapeutic studies.
Fragment research: Experimental work on the LKKTETQ actin-binding region has shown activity in endothelial-cell migration and angiogenesis-related assays. These studies support biological activity of the fragment but remain primarily mechanistic and preclinical.
Full-length thymosin beta-4 research: Full-length thymosin beta-4 has a substantially broader research literature, including animal models and human wound-healing studies. A randomized Phase 2 study involving 73 patients with venous stasis ulcers evaluated topical full-length thymosin beta-4 and reported an acceptable safety profile with exploratory wound-healing findings. That study should not be presented as clinical evidence for TB-500 because the intervention was full-length thymosin beta-4, not the Ac-LKKTETQ fragment.
The major limitation in TB-500 research is the tendency to combine evidence from TB-500, short thymosin beta-4 fragments, and full-length thymosin beta-4 as though they represent the same intervention. They do not.
Questions remain regarding TB-500-specific pharmacokinetics, tissue distribution, formulation, dose-response relationships, long-term safety, and controlled human outcomes. The existing human clinical literature for full-length thymosin beta-4 cannot establish equivalent efficacy or safety for TB-500.
Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis. 2012;4(9):733–738. PMID: 22962027. DOI: 10.1002/dta.1402.
Ho ENM, Kwok WH, Lau MY, Wong AS, Wan TS, Lam KK, Schiff PJ, Stewart BD. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta-4, in equine urine and plasma by liquid chromatography-mass spectrometry. Journal of Chromatography A. 2012;1265:57–69. PMID: 23084823. DOI: 10.1016/j.chroma.2012.09.043.
Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB Journal. 2003;17(14):2103–2105. PMID: 14500546. DOI: 10.1096/fj.03-0121fje.
Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB Journal. 2010;24(7):2144–2151. PMID: 20179146. DOI: 10.1096/fj.09-142307.
Full-length thymosin beta-4 evidence only: Guarnera G, DeRosa A, Camerini R; 8 European sites. The effect of thymosin treatment of venous ulcers. Annals of the New York Academy of Sciences. 2010;1194:207–212. PMID: 20536470. DOI: 10.1111/j.1749-6632.2010.05490.x. This study evaluated full-length thymosin beta-4, not TB-500.
References were checked against supplied and PubMed-indexed primary-source records. Reference five is included as full-length thymosin beta-4 evidence only, not as a TB-500 clinical trial.
The evidence base includes analytical characterization, fragment-level cellular and angiogenesis assays, and a broader full-length thymosin beta-4 literature. Controlled human clinical evidence specific to TB-500 has not been established.
CELLULAR / IN-VITRO EVIDENCE
The LKKTETQ actin-binding region has demonstrated activity in endothelial-cell migration, adhesion, vascular sprouting, and angiogenesis-related experimental systems.
ANIMAL / PRECLINICAL EVIDENCE
The broader thymosin beta-4 literature includes numerous tissue-repair and wound-healing models, but only evidence directly involving the TB-500 fragment should be attributed specifically to TB-500.
Controlled human clinical evidence specific to TB-500 has not been established. Human trials involving full-length thymosin beta-4 should be clearly labeled as evidence for the parent peptide rather than TB-500.
Established within the research record: TB-500 has been analytically identified as Ac-LKKTETQ. The LKKTETQ region is part of the actin-binding domain of thymosin beta-4. Short peptides containing this region show biological activity in experimental angiogenesis and cell-migration models.
Not established: Clinical efficacy of TB-500 in humans; an evidence-based human safety profile for TB-500; and equivalence between TB-500 and full-length thymosin beta-4.
Human safety data specific to TB-500 are insufficient to establish a comprehensive tolerability profile. Safety findings from full-length thymosin beta-4 clinical studies should not be automatically extrapolated to TB-500.
Priority research gaps include TB-500-specific pharmacokinetics, validated pharmaceutical preparations, controlled human trials, dose-response characterization, long-term safety, and independent replication.
The most important interpretive issue is maintaining a clear distinction between TB-500, LKKTETQ-containing experimental fragments, and full-length thymosin beta-4.
EDITORIALLY REVIEWED
LAST REVIEWED
Research profile reviewed for source accuracy, evidence classification, and distinction between TB-500, thymosin beta-4 fragments, and full-length thymosin beta-4.